Bluejay Therapeutics
PrivateLast Round
M&A
Dec 8, 2025
Est. Valuation
$620M
Total Funding Raised
$243M
Momentum Score
25 /100
Company Overview
Bluejay Therapeutics is a biopharmaceutical company that develops therapeutic medicines aimed at providing curative treatments for serious viral and liver diseases, focusing on enhancing adaptive immunity through monoclonal antibodies to combat chronic hepatitis B and D.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bluejay Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Bluejay Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Dec 8, 2025 | ||||
| IPO Announced | Apr 12, 2025 | ||||
| Series C | May 9, 2024 | ||||
| Series B | Aug 16, 2022 | ||||
| Series A | Jun 1, 2021 |
Bluejay Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series C, M&A |
| Yonjin Capital | Series B |
| Innopact | Series B |
| Synergenics | Series B |
| Frazier Life Sciences | M&A, Series C |
| RiverVest Venture Partners | Series C, Series B |
| HBM Healthcare Investments | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 9, 2025
Mirum Pharmaceuticals to acquire treatment for hepatitis D developer.
- Dec 9, 2025
Mirum Pharmaceuticals to acquire the company.
Bluejay Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Bluejay Therapeutics's valuation, stock price, and market status.
